title: Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
abstract: OBJECTIVE
  This review addresses use of monoclonal antibodies and immunoconjugates to treat acute myeloid leukemia.
  
  
  RESULTS
  Monoclonal antibodies used in acute myeloid leukemia have been directed against the antigens CD33, CD45, and CD66. Unconjugated monoclonal antibodies such as lintuzumab have modest activity against overt acute myeloid leukemia but can eliminate minimal residual disease in acute promyelocytic leukemia. Most experience with immunoconjugates is with gemtuzumab ozogamicin, an anti-CD33 monoclonal antibody linked to the potent antitumor antibiotic calicheamicin. Gemtuzumab ozogamicin has shown activity both singly, particularly in acute promyelocytic leukemia, and combined with conventional cytotoxic chemotherapy. Radiolabeled monoclonal antibodies against CD45 and CD66 have also been used to intensify the conditioning regimen before stem cell transplantation. The most promising results were obtained with radiolabeled anti-CD45 antibodies. Antibodies reactive with CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies.
  
  
  CONCLUSIONS
  Both unlabeled monoclonal antibodies and immunoconjugates appear to have a limited role if used as single agents to treat acute myeloid leukemia. These agents hold promise as potentially useful additions to conventional therapy, but the optimal dosing and timing remain to be defined.
authors.affiliation: Department of Hematology, Tor Vergata University Hospital, Rome, Italy. sergio.amadori@ptvonline.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
authors.forename: Roberto
authors.initials: R
authors.lastname: Stasi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015214:Antigens, Differentiation, Myelomonocytic / Q000187:drug effects / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D015214:Antigens, Differentiation, Myelomonocytic; D018796:Immunoconjugates